Skip to content

EBIT at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
AbbVie logo
AbbVieABBV
Boston Scientific logo
Boston ScientificBSX
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
Exelixis logo
ExelixisEXEL

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Calculated from Glaukos’s reported figures.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's EBIT?
Glaukos (GKOS) reported EBIT of -$19.86M in Q1 2026.
How has Glaukos's EBIT changed year-over-year?
Glaukos's EBIT increased by 4.0% year-over-year, from -$20.68M to -$19.86M.
What is the long-term trend for Glaukos's EBIT?
Over 4 years (2021 to 2025), Glaukos's EBIT has grown at a 57.0% compound annual growth rate (CAGR), from -$32.87M to -$199.6M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.